VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Age: 18-75 years old, no limitation in gender      │ Age: 18-75 years old, no limitation in gender      │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Left ventricular ejection fraction (LVEF) ≤ 40%    │ Left ventricular ejection fraction (LVEF) ≤ 40%    │     100 │
│ (ECHO)                                             │ (ECHO)                                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with chronic heart failure (NYHA class II │ Patients with chronic heart failure (NYHA class II │     100 │
│ or III)                                            │ or III)                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ In the past one month, the clinical condition      │ In the past one month, the clinical condition      │     100 │
│ (including history, clinical symptoms and signs)   │ (including history, clinical symptoms and signs)   │         │
│ was relatively stable                              │ was relatively stable                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients on standard treatment of chronic heart    │ Patients on standard treatment of chronic heart    │     100 │
│ failure at the target dose or maximum tolerance    │ failure at the target dose or maximum tolerance    │         │
│ dose for over 1 month ,or unchanged dose in last 1 │ dose for over 1 month ,or unchanged dose in last 1 │         │
│ month                                              │ month                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Understand and sign the informed consent form      │ Understand and sign the informed consent form      │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Atrial fibrillation                                │ Atrial fibrillation                                │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subject underwent cardiac pacemaker treatment      │ Subject underwent cardiac pacemaker treatment      │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subject underwent metal graft treatment            │ Subject underwent metal graft treatment            │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Claustrophobia                                     │ Claustrophobia                                     │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Acute myocardial infarction, cardiac ischemia      │ Acute myocardial infarction, cardiac ischemia      │     100 │
│ indicated by 6-minute walk test, hypertrophic      │ indicated by 6-minute walk test, hypertrophic      │         │
│ cardiomyopathy, constrictive pericarditis,         │ cardiomyopathy, constrictive pericarditis,         │         │
│ significant valve disease or congenital heart      │ significant valve disease or congenital heart      │         │
│ disease, severe pulmonary hypertension             │ disease, severe pulmonary hypertension             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Ischemic heart failure without the                 │ Ischemic heart failure without the                 │     100 │
│ revascularization or undergone the                 │ revascularization or undergone the                 │         │
│ revascularization within last 6 months             │ revascularization within last 6 months             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subject underwent cardiac surgery or               │ Subject underwent cardiac surgery or               │     100 │
│ cerebrovascular events within the previous six     │ cerebrovascular events within the previous six     │         │
│ months                                             │ months                                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects who plan to have cardiac transplantation  │ Subjects who plan to have cardiac transplantation  │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Severe hepatic and renal insufficiency (serum      │ Severe hepatic and renal insufficiency (serum      │     100 │
│ creatinine\>2.0 mg /dl, AST or ALT is five times   │ creatinine>2.0 mg /dl, AST or ALT is five times    │         │
│ higher than the upper limit of normal range)       │ higher than the upper limit of normal range)       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subject needs mechanical ventilation               │ Subject needs mechanical ventilation               │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Chronic heart failure complicated with acute       │ Chronic heart failure complicated with acute       │     100 │
│ hemodynamic disturbance or acute decompensation    │ hemodynamic disturbance or acute decompensation    │         │
│ within last 1 month                                │ within last 1 month                                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Mobitz Type II or III° atrial ventricular          │ Mobitz Type II or III° atrial ventricular          │     100 │
│ block，severe ventricular arrhythmia (polymorphic  │ block，severe ventricular arrhythmia (polymorphic  │         │
│ and frequent premature ventricular beats, frequent │ and frequent premature ventricular beats, frequent │         │
│ non-sustained ventricular tachycardia)             │ non-sustained ventricular tachycardia)             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Female subject is pregnant or plan to become       │ Female subject is pregnant or plan to become       │     100 │
│ pregnant                                           │ pregnant                                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Childbearing-aged female subject who is unmarried  │ Childbearing-aged female subject who is unmarried  │     100 │
│ or dose not bear child                             │ or dose not bear child                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subject with life expectancy less than 6 months as │ Subject with life expectancy less than 6 months as │     100 │
│ assessed by investigators                          │ assessed by investigators                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subject participated in any other clinical trial   │ Subject participated in any other clinical trial   │     100 │
│ within the previous three months                   │ within the previous three months                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subject with previous history of tumor, or current │ Subject with previous history of tumor, or current │     100 │
│ tumor patient, or subject with pre-cancerous       │ tumor patient, or subject with pre-cancerous       │         │
│ disease manifested by pathological examination     │ disease manifested by pathological examination     │         │
│ (such as ductal carcinoma in situ or cervical      │ (such as ductal carcinoma in situ or cervical      │         │
│ epithelial dysplasia)                              │ epithelial dysplasia)                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Examinations (physical examination, X-ray          │ Examinations (physical examination, X-ray          │     100 │
│ examination, type-B ultrasonic detection or other  │ examination, type-B ultrasonic detection or other  │         │
│ methods) reveal that the subject has malignant     │ methods) reveal that the subject has malignant     │         │
│ mass, gland hyperplasia or adenoma with endocrine  │ mass, gland hyperplasia or adenoma with endocrine  │         │
│ activity, or impact on heart, or endocrine         │ activity, or impact on heart, or endocrine         │         │
│ function (such as pheochromocytoma, thyroid        │ function (such as pheochromocytoma, thyroid        │         │
│ enlargement)                                       │ enlargement)                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ The Investigator deemed for whatever reason that   │ The Investigator deemed for whatever reason that   │     100 │
│ the subject is not likely to complete the study or │ the subject is not likely to complete the study or │         │
│ comply with the study procedures (due to           │ comply with the study procedures (due to           │         │
│ administration or any other reason)                │ administration or any other reason)                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Systolic blood pressure \< 90mmHg, or \> 160mmHg   │ Systolic blood pressure < 90mmHg, or > 160mmHg     │      98 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Serum potassium\<3.2mmol/L, or\>5.5mmol/L          │ Serum potassium<3.2mmol/L, or>5.5mmol/L            │      98 │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤═══════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                                     │   Score │
╞═══════════════════════════════════╪═══════════════════════════════════════════════════╪═════════╡
│ Must have minimum age of 18 Years │ Understand and sign the informed consent form     │      36 │
├───────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Must have maximum age of 75 Years │ Subjects who plan to have cardiac transplantation │      37 │
╘═══════════════════════════════════╧═══════════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 99
Average Levenshtein Ratio of individual lines: 95.48275862068965
OverAll Ratio: 97.24137931034483
